Night Shift Work Classified as Probably Carcinogenic to Humans
IARC update evaluation of carcinogenicity of night shift work
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Molecular Characterisation of Non-functional Pancreatic Neuroendocrine Tumours
Robust molecular stratification provides insights into cell lineage correlates
EMA Recommends Extension of Indications for Ibrutinib
New indications concern combination with obinutuzumab for CLL and with rituximab for Waldenström’s macroglobulinaemia
FDA Approves Daratumumab for Multiple Myeloma Ineligible for Autologous Stem Cell Transplant
Approval is based on evidence from the MAIA study
Informed Consent Application for Azacitidine Celgene Received a Positive Opinion from the EMA
Marketing authorisation granted for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Daratumumab Shows Clinical Benefit in Combination With Standard of Care in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
CASSIOPEIA is the first phase III study to evaluate daratumumab in that setting
Population-level Impact of HPV Vaccination
Effectiveness of HPV vaccines in real-world settings based on up to 8 years of post-vaccination follow-up data
EMA Recommends Extension of Indications for Ramucirumab
New indication concerns monotherapy for advanced or unresectable hepatocellular carcinoma with AFP ≥ 400 ng/ml
EMA Recommends Extension of Indications for Atezolizumab
New indication concerns combination treatment with nab-paclitaxel for unresectable locally advanced or metastatic TNBC
Molecular Profiling in Routine Practice for Advanced Cancers
Limited clinical benefit achieved in the ProfiLER study
Japan Becomes the First Country to Approve Entrectinib
Tumour-agnostic medicine is approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours
Clinical Utility of Neoadjuvant Immune Checkpoint Inhibitors in Resectable NSCLC Remains Unknown
More research is also needed to identify optimal biomarkers